Pharmacokinetics and dosimetry of iodine-125-IUdR in the treatment of colorectal cancer metastatic to liver

J Nucl Med. 1996 Apr;37(4 Suppl):29S-32S.

Abstract

The radiotoxicity of 125I is highly sensitive to the site of decay relative to nuclear DNA. This paper describes a new approach, based upon pharmacokinetic clearance of radioactivity from the tumor, with which to quantify the fraction of [125I]IUdR incorporated within the DNA of tumor cells.

Methods: Patients were injected with [125I]IUdR through the hepatic artery. Iodine-131-IUdR was used as a tracer for imaging and quantitation. Both conventional and DNA-level dosimetry were performed.

Results: We calculated that if 15% of the tumor cells were in S phase at the time of injection, there would be 250 decays of 125I in the DNA per tumor cell after an infusion of 5 mCi [125I]IUdR. According to in vitro data based on 5 x 10(8) cells per g tumor, 99% of these cells in S phase would be killed.

Conclusion: The estimate of cell inactivation is strongly dependent on the number of cells per gram and the fraction of cells in S phase at the time of injection, which indicates that repeat injections would be necessary to achieve a therapeutic effect.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Bone Marrow / radiation effects
  • Colorectal Neoplasms / pathology*
  • Hepatic Artery
  • Humans
  • Idoxuridine / administration & dosage
  • Idoxuridine / pharmacokinetics
  • Idoxuridine / therapeutic use*
  • Injections, Intra-Arterial
  • Iodine Radioisotopes / administration & dosage
  • Iodine Radioisotopes / pharmacokinetics
  • Iodine Radioisotopes / therapeutic use*
  • Liver / diagnostic imaging
  • Liver Neoplasms / diagnostic imaging
  • Liver Neoplasms / radiotherapy*
  • Liver Neoplasms / secondary*
  • Radiometry
  • Radionuclide Imaging
  • Radiotherapy Dosage

Substances

  • Iodine Radioisotopes
  • Idoxuridine